BioAge Labs (BIOA) Faces Securities Class Action On Behalf Of IPO Investors After Discontinuing Weight-Loss Drug Trial– Hagens Berman
BioAge Labs, Inc. (BIOA)
Last bioage labs, inc. earnings: 8/3 07:00 am
Check Earnings Report
US:NYSE Investor Relations:
investor.bio-amber.com
Company Research
Source: GlobeNewswire
SAN FRANCISCO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- BioAge Labs (NASDAQ: BIOA), a biopharmaceutical company focused on metabolic diseases, is facing a class-action lawsuit from shareholders who allege the company misled investors about the safety and prospects of a key drug candidate before its initial public offering last September. Hagens Berman urges investors who purchased BioAge shares in the company’s IPO or on the open market and suffered substantial losses to submit your losses now. Defined Class: Purchasers in BioAge Labs, Inc. September 2024 IPO Lead Plaintiff Deadline: Mar. 10, 2025Visit: www.hbsslaw.com/investor-fraud/bioaContact the Firm Now: BIOA@hbsslaw.com 844-916-0895 BioAge Labs, Inc. (BIOA) Securities Class Action: The lawsuit, Soto v. BioAge Labs, Inc., filed in the U.S. District Court for the Northern District of California, centers on the company’s STRIDES Phase 2 clinical trial for azelaprag, an investigational drug. The suit claims that offering documents
Show less
Read more
Impact Snapshot
Event Time:
BIOA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BIOA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIOA alerts
High impacting BioAge Labs, Inc. news events
Weekly update
A roundup of the hottest topics
BIOA
News
- BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Fraud Lawsuit with the Schall Law FirmBusiness Wire
- BioAge Labs, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights – BIOAAccesswire
- Securities Fraud Investigation Into BioAge Labs, Inc. (BIOA) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law FirmBusiness Wire
- Securities Fraud Investigation Into BioAge Labs, Inc. (BIOA) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. CruzBusiness Wire
- Investors who Lost Money on BioAge Labs, Inc. (BIOA) Should Contact Levi & Korsinsky about Pending Class Action - BIOAAccesswire
BIOA
Sec Filings
- 12/20/24 - Form 4
- 11/14/24 - Form SC
- 11/12/24 - Form SC
- BIOA's page on the SEC website